2BB score and signals
TG Therapeutics, Inc.’s current 2BB score is 45 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 47 | Moderate |
| Momentum | 43 | Stable |
| Financial strength | 77 | Strong |
| Quality | 100 | Very Strong |
| Risk | 34 | Low |
Company facts
| CEO | Michael S Weiss |
| Headquarters | Morrisville, North Carolina, United States |
| Founded | 1993 |
| Employees | 399 |
| P/E ratio | 20.29 |
| 52-week range | $26.76 – $59.30 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-01-11 | — | 0.4491 | — | $273.21M |
| 2026-11-02 | — | 0.3692 | — | $252.00M |
| 2026-08-03 | 0.05 | 0.3327 | $240.34M | $234.32M |
| 2026-05-06 | 0.18 | 0.3005 | $204.92M | $200.75M |
Related companies
